Registry following adults with hepatitis B virus infection across Europe
Collects information and samples from people with hepatitis B to guide future studies.
Plain-language title generated from the registry record
Registry title: A Non-interventional Registry for Patients With Hepatitis B Virus Infection
Key facts
- Where
- Hanover, GermanySee the site
Where in Germany
- Hannover Medical SchoolHanover, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hannover Medical School
- Trial code
- NCT05051098
- Record updated
- 5 October 2026
- Original description
In order to tackle the unmet needs in chronic HBV infection, a consortium of clinical partners has gathered to establish a registry for patients with hepatitis B mono- and co-infections. The partners will build up a European-wide registry to be able to stratify patients for upcoming clinical trials.Read full original descriptionShow less
The European HBV Registry: A Joint Initiative of TherVacB and DZIF
In order to tackle the unmet needs in chronic HBV infection, a consortium of clinical partners has gathered to establish a registry for patients with hepatitis B mono- and co-infections. The partners will build up a European-wide registry to be able to stratify patients for upcoming clinical trials.
Extensive analyses of virus and host-specific parameters are to be carried out from these patients. The knowledge gained thereby should contribute to a better understanding of the HBV control and enable patient stratification with regard to immunomodulatory therapies.
Furthermore, hepatitis B patients are to be identified who are willing to participate in future studies to investigate immunotherapies to cure HBV infections (e.g. therapeutic vaccines).
Inclusion: Hepatitis B Virus Infection; TherVacB sub-cohort:; confirmed chronic hepatitis B virus infection: HBsAg positive for at least 1 year prior inclusion; HBeAg status documented for at least 6 months.
Exclusion: clinically relevant concomitant liver diseases (ALD, NASH, Haemochromatosis, Autoimmune hepatitis, AT1, Wilson's disease, primary biliary cirrhosis etc.); co-infection with HIV, HCV (RNA positive),; significant comorbidities (e.g. malignancies); History of hepatocellular carcinoma; age >70 years; TherVacB sub-cohort:; immunosuppressive treatment (> 40 mg Cortisol- equivalent); liver cirrhosis (judged clinically or based on ultrasound/transient elastography).